The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 117... ...
Day 1 (Emerging Safety Science: Biology of Adverse Events) will cover primarily preclinical safety issues, and Day 2 (Emerging Safety Science: Data Mining from the Medical Experience)
|
From page 118... ...
Food and Drug Administration Human Cell System–Based Approaches to Signaling and Biology 8:45–9:40 Moderator: David Jacobson-Kram Associate Director for Pharmacology and Toxicology Office of New Drugs Center for Drug Evaluation and Research U.S. Food and Drug Administration 20 min.
|
From page 119... ...
Toxicogenomics and Assessment of Drug Pharmacology Using Microarrays Mark Cockett Vice President, Applied Genomics Bristol-Myers Squibb Company 20 min. Application of Toxicogenomics to Drug Discovery and to Preclinical Safety Assessment Don Halbert Executive Vice President of Research and Development Iconix Pharmaceuticals 10:20–10:35 Break 20 min.
|
From page 120... ...
Food and Drug Administration 20 min. Metabolomics as an Emerging Technology in Drug Safety Assessment Michael Milburn Chief Scientific Officer Metabolon, Inc.
|
From page 121... ...
Food and Drug Administration 30 min. ALK5: Targeted Investigations of a Targeted Therapy -- Using Laser Capture Microdissection, Flow Cytometry, Immunohistochemical Approaches, and Genomics Kendall Frazier ������������������������������������������� Director of Cellular & Molecular Pathology GlaxoSmithKline, Safety Assessment 25 min.
|
From page 122... ...
(retired) Thomas Caskey, University of Texas HSC at Houston Emerging Safety Science April 23–24, 2007 FDA White Oak Conference Center Silver Spring, MD Tuesday, April 24: Data Mining from Medical Experience Welcome and Opening Remarks 8:30–8:45 Edward Holmes, Workshop Chair Co-Chair, Forum on Drug Discovery, Development, and Translation Executive Deputy Chairman A*
|
From page 123... ...
Food and Drug Administration Gerald Dal Pan Director, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research U.S. Food and Drug Administration 30 min.
|
From page 124... ...
Food and Drug Administration J Paul Seligman, U.S. Food and Drug Administration Ronald Krall, GlaxoSmithKline John Jenkins, U.S.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.